Page last updated: 2024-10-30

mesalamine and Melanoma

mesalamine has been researched along with Melanoma in 1 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Minor, DR1
Chin, K1
Kashani-Sabet, M1

Other Studies

1 other study available for mesalamine and Melanoma

ArticleYear
Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:3

    Topics: Algorithms; Antibodies, Monoclonal; Antigens, CD; Clinical Trials as Topic; Colitis; CTLA-4 Antigen;

2009